SCHEMBL3497376

SCHEMBL3497376

CCN1C(=O)C2(CC1C)CN(C(=O)OC(C)(C)C)CCO2

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RECQL P46063 1/20 0.38
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
EPHX2 P34913 1/20 0.34
USP30 Q70CQ3 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
ATM Q13315 2/20 0.32
GPR119 Q8TDV5 2/20 0.32
BACE1 P56817 1/20 0.32
FAAH O00519 1/20 0.32
NR1H2 P55055 1/20 0.32
TP53 P04637 1/20 0.32
HPGD P15428 1/20 0.32
DPP4 P27487 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3497370 0.79 USP30 (0.45) USP2SMN1; SMN2DDB1CRBNEPHX2
SCHEMBL3498100 0.77 USP30 (0.39) USP2SMN1; SMN2DDB1CRBNEPHX2
SCHEMBL3497910 0.73 DDB1 (0.34) USP2SMN1; SMN2DDB1CRBNEPHX2
SCHEMBL3497603 0.72 USP2 (0.49) USP2SMN1; SMN2RECQLDDB1CRBN
SCHEMBL24716572 0.71 USP2 (0.50) USP2SMN1; SMN2RECQLEPHX2GPR119
SCHEMBL25713743 0.70 USP2 (0.49) USP2SMN1; SMN2RECQLEPHX2MAPT
SCHEMBL24716571 0.70 USP2 (0.49) USP2SMN1; SMN2RECQLDDB1CRBN
SCHEMBL16838402 0.69 USP2 (0.57) USP2SMN1; SMN2RECQLEPHX2MAPT
SCHEMBL22259522 0.69 USP2 (0.50) USP2SMN1; SMN2RECQLEPHX2GPR119
SCHEMBL22594128 0.69 USP2 (0.50) USP2SMN1; SMN2RECQLDDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC USP2 4310/4885SMN1; SMN2 1291/4885RECQL 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.